Analysis of key learnings from discussions around real-world cases between patient associations and industry stakeholders during the APLUSA Breakfast Briefing: how patient studies (BI, RWE, Market Access) help reduce blind spots and improve strategic performance
Introduction
As patient centricity becomes an established standard within the healthcare industry, a critical question emerges: to what extent does integrating the patient voice truly transform decision-making and create value?
The cases presented and discussions with patient representatives and associations highlight a fundamental shift. The patient voice is no longer simply enriching existing analyses. It reveals structural gaps between theoretical decision-making models and lived realities, whether related to development assumptions, care pathways, or real-world adoption conditions.
By combining approaches from Business Intelligence, Real-World Evidence (RWE), Market Access, Medical Affairs, and Patient Centricity, one conclusion becomes clear: the value of patient studies does not lie in generating additional insights, but in their ability to reframe decisions, correct blind spots, and activate tangible performance drivers.
1. Towards Reality-Driven R&D: Addressing Blind Spots in Development Assumptions
Several presentations illustrated the patient’s ability to bring forward issues overlooked by traditional research frameworks. The example of cognitive impairments associated with certain hormone therapies in oncology, initially absent from scientific agendas, provides a particularly compelling illustration.
This case highlights a structural limitation of traditional approaches: while scientifically robust, research assumptions may remain partially disconnected from the impacts experienced in everyday life.
The contribution of patients therefore goes beyond enriching knowledge. It enables the reprioritization of research efforts by directing them toward dimensions that hold genuine value for patients. This shift is particularly important in a context where health authorities are increasingly assessing the perceived value of innovations.
From this perspective, early patient involvement acts as a strategic risk mitigation mechanism, increasing the likelihood of developing approaches that are relevant, differentiated, and capable of generating value.
2. Understanding Access Gaps: From Theoretical Pathways to Real-World Journeys
The study conducted in the field of obesity highlighted a recurring phenomenon: the existence of a significant gap between care pathways as they are designed and those actually followed by patients.
The analysis revealed that these gaps cannot be explained solely by organizational constraints, but also by more subtle factors, such as the difficulty of discussing certain topics during consultations and perceptions associated with the disease.
This type of insight leads to a reconsideration of the nature of access challenges. The issue is no longer simply about structuring an offering, but about understanding what concretely prevents its activation.
For healthcare stakeholders, this perspective opens up a major strategic opportunity. By precisely identifying points of disruption within the real-world patient journey, it becomes possible to act on the determinants of access to care and, by extension, improve patient uptake and management rates.
3. The Test of Use: Innovation Confronted with the Reality of Practice
Discussions also highlighted a critical point in the innovation journey: the transition from demonstrated efficacy to actual use.
Several examples illustrated situations in which solutions that were conceptually or technologically relevant failed to be adopted in practice because they had not been designed with patients’ real-life constraints in mind.
This observation reflects a profound evolution in the concept of value. The impact of an innovation is no longer measured solely by its intrinsic performance, but by its ability to integrate into patients’ lifestyles, habits, and specific constraints.
In this context, co-creation emerges not merely as a methodological principle, but as an operational condition for success. It enables the alignment of developed solutions with real-world usage patterns, thereby maximizing their impact, particularly in terms of adherence and persistence.
4. Access to Patients as a Differentiating Factor: Towards an Ecosystem Approach
Another major development highlighted was the ability to rapidly access relevant patient populations. Initiatives built around patient communities demonstrated that it is possible to mobilize a large number of participants for targeted studies within just a few days.
At the same time, the fragmented and dense patient association landscape makes such access complex and heterogeneous.
This tension between abundance and accessibility is transforming the nature of competitive advantage. Competitive advantage no longer relies solely on the ability to generate analyses, but on the capacity to build relational ecosystems that enable seamless access to patients.
This shift is significant. It directly impacts the speed of study execution, the ability to generate insights, and more broadly, the agility of organizations in decision-making.
5. Structuring Collaborations: Balancing Patient Recognition and Systemic Constraints
Discussions with patient association representatives highlighted a persistent tension between recognizing the role of patients and the constraints governing interactions with industry stakeholders.
This tension underscores the fact that the transition toward truly collaborative and integrated models cannot rely on isolated initiatives. Rather, it requires structured frameworks capable of combining engagement, transparency, and compliance.
Within this context, the structuring of collaborations emerges as a lever for professionalizing relationships among stakeholders. It helps strengthen the credibility of initiatives while maximizing their effectiveness and reach.
6. From Insight Generation to Practice Transformation
Finally, one overarching lesson stands out: the value of a study depends less on the richness of the data collected than on the ability to translate it into action.
Several cases demonstrated that despite generating a substantial volume of findings, some initiatives struggled to produce a tangible impact on practices or organizations. Conversely, other approaches showed that structured activation of learnings could influence care pathways and even the organization of the healthcare system itself.
This observation calls for a change in mindset: studies can no longer be viewed as analytical deliverables alone, but as vehicles for transformation. Their design must incorporate activation mechanisms and impact levers from the outset.
Summary: Differentiated Impacts Across Functions
The lessons derived from the business cases presented and the discussions make it possible to identify specific impacts across functions:
- In R&D, a stronger alignment between development assumptions and patient experience reduces strategic risk and enhances the relevance of development programs.
- In Market Access, integrating real-world perspectives helps document previously invisible dimensions and strengthens value demonstrations.
- In Business Intelligence, it enriches the understanding of behaviors and provides new perspectives on adoption drivers.
- In the field, it improves the effectiveness of interactions and the ability to support patients throughout their care journey.
- At the strategic level, it enables organizations to anticipate healthcare system evolutions and guide investments more effectively.
Conclusion
The insights generated during the APLUSA Breakfast Briefing illustrate a profound evolution in the role of patients within the healthcare system. Far from being mere contributors, patients are becoming full participants in the creation of value.
This transformation is not based solely on listening more closely to patients, but on the ability to integrate patient experience into decision-making processes at every level. It requires rethinking existing models, accepting the need to challenge certain assumptions, and structuring approaches capable of connecting insight to action.
In this context, the question is no longer whether the patient voice should be integrated, but how it can be leveraged as a driver of transformation for decision-making, care pathways, and ultimately, the performance of healthcare strategies.
